Como Centrum Okulistyki Sp. z o.o.

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Macular degeneration3 trials

Phase

• Phase 32 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Amgen1 trial
• Rophibio Inc.1 trial
• Samsung Bioepis Co., Ltd.1 trial

Running trials

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV

  NCT07550504· Phase 2· Samsung Bioepis Co., Ltd.· Source

• Completed

  A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration

  2023-509206-29-00· Phase 3· Rophibio Inc.· Source